Chronic Myeloid LeukaemiaThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

2342 records returned

The Interferon Consensus Sequence Binding Protein (ICSBP/IRF8) Activates Transcription of the FANCF Gene during Myeloid Differentiation [Transcription, Chromatin, and Epigenetics]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The interferon consensus sequence binding protein (ICSBP) is an interferon regulatory transcription factor with leukemia-suppressor activity. ICSBP regulates genes that are involved in phagocyte function, proliferation, and apoptosis. In murine models ICSBP deficiency results in a myeloproliferative disorder (MPD) with increased mature neutrophils. Over time this MPD progresses to acute myeloid leukemia (AML), suggesting that ICSBP deficiency is adequate for MPD, but additional genetic lesions are required for AML. The hypothesis of these studies is that dysregulation of key target genes predisposes to disease progression ...
Source: Journal of Biological Chemistry - November 20, 2009 Category: Chemistry Authors: Saberwal, G., Horvath, E., Hu, L., Zhu, C., Hjort, E., Eklund, E. A. Tags: Transcription, Chromatin, and Epigenetics Source Type: journals

Suppression of ERK signaling evokes autocrine Fas-mediated death in arachidonic acid-treated human chronic myeloid leukemia K562 cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Arachidonic acid (AA)-induced apoptotic death of K562 cells (human chronic myeloid leukemic cells) was characteristic of reactive oxygen species (ROS) generation and mitochondrial depolarization. N-Acetylcysteine pretreatment rescued viability of AA-treated cells and abolished mitochondrial depolarization. In contrast to no significant changes in phospho-JNK and phospho-ERK levels, AA evoked notable activation of p38 MAPK. Unlike that of JNK and p38 MAPK, ERK suppression further reduced the viability of AA-treated cells. Increases in Fas/FasL protein expression, caspase-8 activation, the production of tBid and the loss of ...
Source: Journal of Cellular Physiology - November 20, 2009 Category: Cytology Authors: Ku-Chung Chen, Wen-Hsin Liu, Long-Sen Chang Source Type: journals

Dasatinib Impedes Growth of Ovarian Cancer Cells in Laboratory StudiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Laboratory studies indicate that dasatinib, a drug used in treating chronic myeloid leukemia, may limit the growth and invasion of ovarian cancer cells. Researchers at the University of California at Los... (Source: OncologySTAT What Patients Are Reading)
Source: OncologySTAT What Patients Are Reading - November 18, 2009 Category: Cancer & Oncology Source Type: info

Asuragen Signs Development and Worldwide Distribution Agreement with Life TechnologiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Life Technologies to distribute Asuragens BCR/ABL1 leukemia assay for use on Applied Biosystems real-time PCR instrument AUSTIN, Texas, Nov 18--(HSMN NewsFeed)--Asuragen, Inc. announced today that it has entered into an exclusive agreement with Life Te... Diagnostics, Oncology, DistributionAsuragen, Life Technologies Corp, BCR/ ABL1 assay, chronic myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 18, 2009 Category: Pharmaceuticals Source Type: news

Chronic myelogenous leukemia and benzene exposure: a systematic review and meta-analysis of the case-control literature.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Benzene exposure is well demonstrated as a cause of acute myelogenous leukemia, but not of chronic myelogenous leukemia. Previous literature reviews based on case series and cohort studies have not shown an association. We have now conducted a literature search for case-control studies that examine the association between benzene exposure and chronic myelogenous leukemia. Six case-control studies have been found. These derive from occupational groups, cancer registries, and a clinical laboratory. Their exposure ascertainments are all based on job histories, job-exposure matricies, or industrial hygiene data. The odds r...
Source: Chemico-Biological Interactions - November 18, 2009 Category: Molecular Biology Authors: Lamm SH, Engel A, Joshi KP, Byrd DM, Chen R Tags: Chem Biol Interact Source Type: journals

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dasatinib, a highly potent BCR-ABL inhibitor, is an effective treatment for patients with chronic myeloid leukemia in chronic phase (CML CP) after resistance, suboptimal response, or intolerance to prior imatinib. In a phase 3 dose optimization trial in patients with CML CP (CA180-034), the occurrence of pleural effusion was significantly minimized with dasatinib 100 mg once daily (QD) compared with other treatment arms (70 mg twice daily [twice daily], 140 mg QD, or 50 mg twice daily).To investigate the occurrence and management of pleural effusion during dasatinib treatment, and efficacy in patients with or without pleur...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Kimmo Porkka, H. Jean Khoury, Ronald L. Paquette, Yousif Matloub, Ritwik Sinha, Jorge E. Cortes Source Type: journals

Differences in mouse models of diabetes mellitus in studies of male reproductionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Diabetes Mellitus (DM) has been found to have subtle yet profound effects on the metabolic status of the testis, the expression of numerous spermatogenic genes and is associated with increased numbers of sperm with nuclear DNA damage. The precise mechanism causing these detrimental effects remains unknown. The presence of increased levels of the most prominent member (carboxymethyllysine [ndash] CML) of the advanced glycation end product adducts and their receptor (RAGE) in the reproductive tract of DM men has provided a new avenue for research. As there are suspicions that the antibiotic (streptozotocin [ndash] STZ) emplo...
Source: International Journal of Andrology - November 17, 2009 Category: Sexual Medicine Authors: J. O'Neill, A. Czerwiec, I. Agbaje, J. Glenn, A. Stitt, N. McClure, C. Mallidis Source Type: journals

Disappearance of Lentigines in a Patient Receiving Imatinib Treatment for Familial Gastrointestinal Stromal Tumor Syndrome [Observation]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The potential association between a specific genetic mutation and pigmentation changes secondary to imatinib therapy may account for the variety in presentation of this potential side effect. Further genetic studies paired with melanocyte-specific or c-kit–specific stains of affected tissue are warranted to better understand the relationship between the genetic mutation and the effect of imatinib on pigmentation. (Source: Archives of Dermatology)
Source: Archives of Dermatology - November 16, 2009 Category: Dermatology Authors: Campbell, T., Felsten, L., Moore, J. Tags: Oncology, Oncology, Other, Dermatology, Dermatologic Disorders, Nevi, Dermatologic Disorders, Other, Drug Therapy, Adverse Effects, Drug Therapy, Other, Gastroenterology, Gastrointestinal Diseases, Genetics, Genetic Disorders Observation Source Type: journals

NICE issues draft recommendations (ACD) on dasatinib and nilotinib for chronic myeloid leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: NICE Area: News The Department of Health has asked NICE to produce guidance on the use of dasatinib and nilotinib for imatinib-resistant and/or intolerant for patients with chronic myeloid leukaemia (CML) in the NHS in England and Wales. The Appraisal Committee has published its preliminary recommendations for consultation, as follows: . Dasatinib and nilotinib are not recommended for the treatment of CML in people for whom treatment with imatinib has failed because of imatinib resistance and/or intolerance . People who are currently receiving dasatinib or nilotinib for the treatment of CML ...
Source: NeLM - Oncology - November 16, 2009 Category: Cancer & Oncology Source Type: organizations

Differences in mouse models of diabetes mellitus in studies of male reproduction.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Diabetes Mellitus (DM) has been found to have subtle yet profound effects on the metabolic status of the testis, the expression of numerous spermatogenic genes and is associated with increased numbers of sperm with nuclear DNA damage. The precise mechanism causing these detrimental effects remains unknown. The presence of increased levels of the most prominent member (carboxymethyllysine - CML) of the advanced glycation end product adducts and their receptor (RAGE) in the reproductive tract of DM men has provided a new avenue for research. As there are suspicions that the antibiotic (streptozotocin - STZ) employed to i...
Source: International Journal of Andrology - November 16, 2009 Category: Urology & Nephrology Authors: O'Neill J, Czerwiec A, Agbaje I, Glenn J, Stitt A, McClure N, Mallidis C Tags: Int J Androl Source Type: journals

Leukemia Med May Also Fight Ovarian CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
U.S. medical scientists say they've discovered the drug Sprycel, approved for chronic myeloid leukemia, also is effective against ovarian cancer cells. (Source: Cancercompass News: Gynecological Cancer)
Source: Cancercompass News: Gynecological Cancer - November 15, 2009 Category: Cancer & Oncology Source Type: news

Detection of pulmonary complications in common variable immunodeficiencyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Touw CML, van de Ven AA, de Jong PA, Terheggen-Lagro S, Beek E, Sanders EAM, van Montfrans JM. Detection of pulmonary complications in common variable immunodeficiency.Pediatr Allergy Immunol 2009.© 2009 John Wiley & Sons A/S Pulmonary complications are frequently observed in common variable immunodeficiency (CVID). We reviewed the literature related to radiologic imaging techniques and pulmonary function tests (PFT) for diagnosing pulmonary complications in CVID. Scientific publications related to CVID (or primary hypogammaglobulinemia), pulmonary complications, PFT, chest X-ray (CXR), and high-resolution computed tomogr...
Source: Pediatric Allergy and Immunology - November 13, 2009 Category: Allergy & Immunology Authors: Catharina M. L. Touw, Annick A. van de Ven, Pim A. de Jong, Suzanne Terheggen-Lagro, Erik Beek, Elisabeth A. M. Sanders, Joris M. van Montfrans Source Type: journals

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-upEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report on 48 chronic myeloid leukemia patients sequentially treated with 3 TKIs: 34 with dasatinib after imatinib/nilotinib failure and 14 with nilotinib after imatinib/dasatinib failure. Before the third TKI, 25 patients were in chronic phase (CP), 10 in accelerated phase (AP), and 13 in blast phase (BP). Best response to third TKI in CP was 5 major molecular responses (MMR), 3 complete cytogenetic (CCyR), 2 partial cytogenetic (PCyR), 3 minor cytogenetic (mCyR), 6 complete hematologic responses (CHR), and 6 with no response (NR). In AP, 1 patient achieved MMR, 1 CCyR, 2 PCyR, 1 mCyR, 4 CHR, and 1 NR. In BP, 1 achieved...
Source: Blood - November 12, 2009 Category: Hematology Authors: Garg, R. J., Kantarjian, H., O'Brien, S., Quintas-Cardama, A., Faderl, S., Estrov, Z., Cortes, J. Tags: Free Research Articles, myeloid Neoplasia, Clinical Trials and Observations Source Type: journals

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinibEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agents are well tolerated, but potent and as such should be monitored for potentially serious side-effects like fluid retention and pleural effusions. Here we present key clinical trial data and safety considerations for all FDA approved TKIs in context for effective management of fluid retention and pleural effusions. Altering the dasatinib regimen from 70 mg twice daily to 100 mg daily reduces the risk of pleural effusi...
Source: Journal of Hematology and Oncology - November 12, 2009 Category: Hematology Authors: David MasielloGerry GorospeAllen Yang Source Type: journals

Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Suberoylanilide hydroxamic acid (SAHA) is an inhibitor of histone deacetylases (HDACs) which is being introduced into clinic for the treatment of hematological diseases. We studied the effect of this compound on six human hematopoietic cell lines (JURL-MK1, K562, CML-T1, Karpas-299, HL-60, and ML-2) as well as on normal human lymphocytes and on leukemic primary cells. SAHA induced dose-dependent and cell type-dependent cell death which displayed apoptotic features (caspase-3 activation and apoptotic DNA fragmentation) in most cell types including the normal lymphocytes. At subtoxic concentrations (0.5-1 µM), SAHA increase...
Source: Journal of Cellular Biochemistry - November 12, 2009 Category: Biochemistry Authors: Kate[rcaron]ina Ku[zcaron]elová, Michaela Pluskalová, Barbora Brodská, Petra Otev[rcaron]elová, Klára Elknerová, Dana Grebe[ncaron]ová, Zbyn[ecaron]k Hrkal Source Type: journals

FDA Approved Leukemia Drug Shows Promising Activity In Ovarian Cancer CellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 11, 2009 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

FDA Approved Leukemia Drug Shows Promising Activity In Ovarian Cancer CellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. (Source: Lymphoma / Leukemia News From Medical News Today)
Source: Lymphoma / Leukemia News From Medical News Today - November 11, 2009 Category: Hematology Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Chronic Myelogenous Leukemia (CML)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Chronic Myelogenous Leukemia (CML)Category: Doctor's ViewsCreated: 11/11/2009 2:29:00 PMLast Editorial Review: 11/11/2009 2:29:15 PM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 11, 2009 Category: Cancer & Oncology Source Type: consumer

Kareem Abdul-Jabbar Has CML Form of LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Kareem Abdul-Jabbar Has CML Form of LeukemiaCategory: Health NewsCreated: 11/11/2009 9:41:00 AMLast Editorial Review: 11/11/2009 9:41:07 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 11, 2009 Category: Cancer & Oncology Source Type: consumer

Chronic Myelogenous Leukemia (CML)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Chronic Myelogenous Leukemia (CML)Category: Doctor's ViewsCreated: 11/11/2009 2:29:00 PMLast Editorial Review: 11/11/2009 2:29:15 PM (Source: MedicineNet Crohn's Disease General)
Source: MedicineNet Crohn's Disease General - November 11, 2009 Category: Gastroenterology Source Type: consumer

Chronic Myelogenous Leukemia (CML)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Chronic Myelogenous Leukemia (CML)Category: Doctor's ViewsCreated: 11/11/2009 2:29:00 PMLast Editorial Review: 11/11/2009 2:29:15 PM (Source: MedicineNet Senior Health General)
Source: MedicineNet Senior Health General - November 11, 2009 Category: Geriatrics Source Type: consumer

Kareem Abdul-Jabbar Has CML Form of LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - November 11, 2009 Category: Journals (General) Source Type: info

ChemGenex Announces FDA Accepts NDA For Omapro™ (Omacetaxine Mepesuccinate) And Grants The Filing Priority Review StatusEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the U.S. Food & Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 11, 2009 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

ChemGenex Announces FDA Accepts NDA For Omapro™ (Omacetaxine Mepesuccinate) And Grants The Filing Priority Review StatusEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the U.S. Food & Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. The NDA has also been granted Priority Review. (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - November 11, 2009 Category: Cancer & Oncology Tags: Lymphoma / Leukemia / Myeloma Source Type: news

FDA Approved Leukemia Drugs Shows Promise In Ovarian Cancer CellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The drug Sprycel, approved for use by the US Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a new study has found. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 11, 2009 Category: Science Source Type: news

Apoptosis Induction in Human Leukemic Cells by a Novel Protein Bengalin, Isolated from Indian Black Scorpion Venom: through Mitochondrial Pathway and Inhibition of Heat Shock Proteins.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Scorpion venom possesses protein toxins having numerous biological activities, some of which are potentially anticancerous. Previously we had reported antiproliferative activity of the venom of Indian black scorpion, Heterometrus bengalensis Koch. Here we have isolated and purified a novel protein named Bengalin (72kD) from the venom, responsible for antiproliferative and apoptogenic activities against human leukemic cells U937 (histiocytic lymphoma) and K562 (chronic myelogenous leukemia). N-terminal sequence of first 20 amino acids of Bengalin was G-P-L-T-I-L-H-I-N-D-V-H-A-A/R-F-E-Q/G-F/G-N-T. Bengalin induced cell g...
Source: Chemico-Biological Interactions - November 11, 2009 Category: Molecular Biology Authors: Gupta SD, Gomes A, Debnath A, Saha A, Gomes A Tags: Chem Biol Interact Source Type: journals

Basketball Legend Kareem Abdul-Jabbar Announces He Has Been Diagnosed With Chronic Myeloid Leukemia; Aims To Inspire OthersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK, November 10 /PRNewswire/ -- Kareem Abdul-Jabbar, one of the greatest basketball players of all time, known for his unblockable signature "sky hook" shot, has announced that he was diagnosed late last year with a rare type of blood... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 10, 2009 Category: Pharmaceuticals Source Type: news

WATCH: Kareem Adul-Jabbar Battles LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The basketball legend has been diagnosed with chronic myeloid leukemia. (Source: ABC News: Health)
Source: ABC News: Health - November 10, 2009 Category: Consumer Health News Source Type: news

NBA Great Abdul-Jabbar Has Rare Form Of LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Kareem Abdul-Jabbar is being treated for a rare form of leukemia, and the basketball great said his prognosis is encouraging. The NBA's all-time leading scorer was diagnosed last December with chronic myeloid leukemia, he told The Associated Press on Monday. The 62-year-old Abdul-Jabbar said his doctor didn't give any guarantees, but informed him: "You have a very good chance to live your life out and not have to make any drastic changes to your lifestyle." (Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire)
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 10, 2009 Category: Consumer Health News Source Type: consumer

Nilotinib Meets Primary Endpoint in Pivotal Trial Against Imatinib as First-Line Treatment in Chronic Myeloid Leukemia PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Novartis announced recently that nilotinib (Tasigna) 200-mg capsules met its primary endpoint in the first head-to-head comparison with the company’s groundbreaking drug imatinib mesylate (Gleevec) tablets. Nilotinib produced faster and deeper responses than imatinib when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Nilotinib was well tolerated in the study. (Source: Cancer Network)
Source: Cancer Network - November 10, 2009 Category: Cancer & Oncology Source Type: info

Kareem Abdul-Jabbar Has CML Form of LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Basketball legend Kareem Abdul-Jabbar has announced that he's suffered from leukemia for nearly a year. (Source: WebMD Health)
Source: WebMD Health - November 10, 2009 Category: Consumer Health News Source Type: news

SMC accepts use of filgrastim (Ratiograstim®) in NHSScotlandEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium (SMC) has accepted for use within NHSScotland filgrastim (Ratiograstim) for the following licensed indications: 1. Reduction in the duration of neutropenia and the incidence of febrile neutropenia (FN) in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). 2. Reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation con...
Source: NeLM - Haematology - November 10, 2009 Category: Hematology Source Type: organizations

Carboxymethyl-Lysine Levels Linked to Mortality in Older AdultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Increased plasma carboxymethyl-lysine (CML), an advanced glycation end product (AGE), is associated with higher mortality from all causes and from cardiovascular disease in older adults, new research shows. Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - November 9, 2009 Category: Pathology Tags: Internal Medicine Source Type: info

FDA approved leukemia drugs shows promise in ovarian cancer cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(University of California - Los Angeles) The drug Sprycel, approved for use by the US Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 9, 2009 Category: Global & Universal Source Type: news

Novel complex translocation involving 5 different chromosomes in a chronic myeloid leukemia with Philadelphia chromosome: a case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The reported rearrangement developed most probably in one initial step and had no influence on a good response during Imatinib treatment. (Source: BioMed Central)
Source: BioMed Central - November 9, 2009 Category: Journals (General) Authors: Walid Al AchkarAbdulsamad WafaHasmik MkrtchyanFaten MoassassThomas Liehr Source Type: journals

Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients With BCR-ABL T315I MutationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In patients with BCR-ABL–positive (Ph+) leukemia, the T315I mutation is associated with a high degree of resistance to imatinib, dasatinib, and nilotinib. Little published information exits regarding the... The... (Source: OncologySTAT Journal Scans)
Source: OncologySTAT Journal Scans - November 7, 2009 Category: Cancer & Oncology Source Type: journals

The Calmodulin-related Calcium Sensor CML42 Plays a Role in Trichome Branching [Mechanisms Of Signal Transduction]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Calcium (Ca2+) is a key second messenger in eukaryotes where it regulates a diverse array of cellular processes in response to external stimuli. An important Ca2+ sensor in both animals and plants is calmodulin (CaM). In addition to evolutionarily conserved CaM, plants possess a unique family of CaM-like (CML) proteins. The majority of these CMLs have not yet been studied, and investigation into their physical properties and cellular functions will provide insight into Ca2+ signal transduction in plants. Here we describe the characterization of CML42, a 191-amino acid Ca2+-binding protein from Arabidopsis. Ca2+ binding to ...
Source: Journal of Biological Chemistry - November 6, 2009 Category: Chemistry Authors: Dobney, S., Chiasson, D., Lam, P., Smith, S. P., Snedden, W. A. Tags: Mechanisms Of Signal Transduction Source Type: journals

Synthesis, characterization and anticancer activity of new palladacycles derived from chiral [alpha]-diiminesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Optically pure [alpha]-diimines quantitatively obtained in solvent-free conditions starting from 2,3-butanedione and (S)-(-)-1-phenylethylamine and (S)-(-)-1-(4-methylphenyl)ethylamine, respectively, yielded the new chiral mono-Pd complexes 2a-b, which have been partly characterized by IR, 1H- and 13C-NMR spectroscopies along with MS-FAB+ spectrometry. The crystal and molecular structure for palladacycle 2a has been fully confirmed by single-crystal X-ray studies. Studies in vitro of 2a-b have displayed growth inhibition against different classes of cancer: leukemia (K-562 CML), colon cancer (HCT-15), breast cancer (MCF-7)...
Source: Applied Organometallic Chemistry - November 6, 2009 Category: Chemistry Authors: Sandra Cruz, Sylvain Bernès, Pankaj Sharma, Rosa Vazquez, Guadalupe Hernández, Roberto Portillo, René Gutiérrez Source Type: journals

Bcr-Abl fusion sequences do not induce immune responses in mice when administered in mouse polyomavirus based virus-like particles.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Mouse polyomavirus-like particles (MPyV-VLPs) carrying inside a fragment of the Bcr-Abl hybrid protein containing the epitope of chronic myeloid leukemia fusion region were prepared. A sequence encoding 171 amino acids covering Bcr-Abl breakpoint was fused to the C-terminal part of VP3 minor protein connecting it to the VP1 capsomeres. Chimeric particles, the Bcr-Abl VLPs, were tested for their ability to induce Bcr-Abl specific immune response in mice after their intranasal (i.n.) or intraperitoneal (i.p.) administration without any other adjuvants. Bcr-Abl VLPs induced strong anti-VP1 immune response in both i.n. and...
Source: International Journal of Oncology - November 5, 2009 Category: Cancer & Oncology Authors: Hrusková V, Morávková A, Babiarová K, Ludvíková V, Fric J, Vonka V, Forstová J Tags: Int J Oncol Source Type: journals

BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase C{beta}Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder maintained by cancer stem cells. To target this population, we investigated the mechanism of action of BMS-214662, developed as a farnesyl transferase inhibitor (FTI) and unique in inducing apoptosis in these cells. By contrast, a related congener and equally effective FTI, BMS-225975 does not induce apoptosis, indicating a novel mechanism of action. BMS-214662 significantly and selectively induced apoptosis in primitive CD34+38– CML compared with normal cells. Apoptosis proceeded via the intrinsic pathway: Bax conformational changes, loss of mitoch...
Source: Blood - November 5, 2009 Category: Hematology Authors: Pellicano, F., Copland, M., Jorgensen, H. G., Mountford, J., Leber, B., Holyoake, T. L. Tags: Hematopoiesis and Stem Cells, myeloid Neoplasia Source Type: journals

Structural Analysis of DFG-in and DFG-out Dual Src-Abl Inhibitors Sharing a Common Vinyl Purine TemplateEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bcr-Abl is the oncogenic protein tyrosine kinase responsible for chronic myeloid leukemia (CML). Treatment of the disease with imatinib (Gleevec) often results in drug resistance via kinase mutations at the advanced phases of the disease, which has necessitated the development of new mutation-resistant inhibitors, notably against the T315I gatekeeper mutation. As part of our efforts to discover such mutation resistant Abl inhibitors, we have focused on optimizing purine template kinase inhibitors, leading to the discovery of potent DFG-in and DFG-out series of Abl inhibitors that are also potent Src inhibitors. Here we pre...
Source: Chemical Biology and Drug Design - November 5, 2009 Category: Biology Authors: Tianjun Zhou, Lois Commodore, Wei-Sheng Huang, Yihan Wang, Tomi K. Sawyer, William C. Shakespeare, Tim Clackson, Xiaotian Zhu, David C. Dalgarno Source Type: journals

Kareem Abdul Jabbar Diagnosed with CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Basketball legend Kareem Abdul Jabbar has revealed that he has battled and managed a cancer diagnosis for almost a year. The 62 year old suffers from Philadelphia chromosome-positive chronic myeloid leukemia, a rare form of the disease. His leukemia is currently in remission. What I find admirable is that while many celebrities choose not to discuss their health in public, Kareem Abdul Jabbar is doing the total opposite. He has become a full fledged advocate for the disease, devoting a Facebook page to it and also Twitters about it regularly. He has discussed in detail his symptoms and treatment in hopes that it may help ...
Source: About.com Cancer - November 4, 2009 Category: Cancer & Oncology Source Type: consumer

ARIAD's AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL InhibitorEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
~Paper Features Design and Preclinical Characterization of AP24534 ~ Data Demonstrate Inhibition of all Known Variants of the CML Target Protein CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 2, 2009 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 3, 2009 Category: Pharmaceuticals Source Type: clinical trials

Health News of the DayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
is a daily summary made from the selected links I post on Twitter. It is in a bullet points format with links to the original sources which include 350 RSS feeds that produce about 2,500 items per day:How long does hepatitis B vaccine protection last? More than 2 decades http://bit.ly/4lhMlHLarge trials required to clarify whether sodium bicarbonate has value for prevention of contrast-induced nephropathy http://bit.ly/yOE45List of Medical Journal Feeds Arranged by Topic - the University of Wisconsin http://bit.ly/4zxxdgNYT interviews researcher behind Gleevec for CML, "converting a fatal cancer into a manageable chronic ...
Source: Clinical Cases and Images - November 3, 2009 Category: Journals (General) Tags: Health News of the Day Source Type: info

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Thomas O'Hare, William C. Shakespeare, Xiaotian Zhu, Christopher A. Eide, Victor M. Rivera, Frank Wang, Lauren T. Adrian, Tianjun Zhou, Wei-Sheng Huang, Qihong Xu, Chester A. Metcalf, Jeffrey W. Tyner, Marc M. Loriaux, Amie S. Corbin, Scott Wardwell, Yaoyu Ning, Jeffrey A. Keats, Yihan Wang, Raji Sundaramoorthi, Mathew Thomas, Dong Zhou, Joseph Snodgrass, Lois Commodore, Tomi K. Sawyer, David C. Dalgarno, Michael W.N. Deininger, Brian J. Druker, Tim Clackson. Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutatio...
Source: Cancer Cell - November 3, 2009 Category: Cancer & Oncology Source Type: journals

Chronic Myeloid Leukemia: An update of concepts and management recommendations of European LeukemiaNetEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: J Clin Oncol Area: News A review and update of the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukaemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs) has been published early online in the Journal of Clinical Oncology. In summary, initial treatment was confirmed as imatinib 400mg daily, which should be continued indefinitely in optimal responders. Suboptimal responders may continue on imatinb, at the same or higher dose, or may be eligible for investigational therapy with second-generation TKIs. In cases of imatinib failure, second...
Source: NeLM - Oncology - November 3, 2009 Category: Cancer & Oncology Source Type: organizations

The Growth Factor Independence-1 (Gfi1) Is Overexpressed in Chronic Myelogenous Leukemia.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The activation of ABL tyrosine kinase in BCR/ABL-positive chronic myelogenous leukemia (CML) leads to a diversity of biological changes related to the pathogenesis of the disease. In CML patients, we determined the expression of growth factor independence-1 (Gfi1), a transcription repressor with weak oncogenic activity. Our data demonstrated that the Gfi1 mRNA level in both the mononuclear cells and purified CD34(+) cells from CML were significantly higher as measured by quantitative real-time PCR. Using flow cytometry and Western blot, we also showed that the Gfi1 protein content was increased in CML CD34(+) cells. Th...
Source: Acta Haematologica - November 2, 2009 Category: Hematology Authors: Huang M, Hu Z, Chang W, Ou D, Zhou J, Zhang Y Tags: Acta Haematol Source Type: journals

Individual telomere lengths in chronic myeloid leukemia.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Chronic myeloid leukemia (CML) is a neoplasia characterized by proliferation of a myeloid cell lineage and chromosome translocation t(9;22) (q34;q11.2). As in the case of most cancers, the average telomere length in CML cells is shorter than that in normal blood cells. However, there are currently no data available concerning specific individual telomere length in CML. Here, we studied telomere length on each chromosome arm of CML cells. In situ hybridization with peptide nucleic acid probes was performed on CML cells in metaphase. The fluorescence intensity of each specific telomere was converted into kilobases accord...
Source: Neoplasia - November 1, 2009 Category: Cancer & Oncology Authors: Samassekou O, Ntwari A, Hébert J, Yan J Tags: Neoplasia Source Type: journals

ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The intracellular ABC transporter A3 is expressed in chronic myeloid leukemia progenitor cells and may contribute to intrinsic imatinib resistance by facilitating lysosomal sequestration in chronic myeloid leukemia cells. PMID: 19880777 [PubMed - in process] (Source: Haematologica)
Source: Haematologica - November 1, 2009 Category: Hematology Authors: Chapuy B, Panse M, Radunski U, Koch R, Wenzel D, Inagaki N, Haase D, Truemper L, Wulf GG Tags: Haematologica Source Type: journals

The Growth Factor Independence-1 (Gfi1) Is Overexpressed in Chronic Myelogenous LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Acta Haematol 2010;123:1-5 (DOI:10.1159/000253856) (Source: Karger Publishers)
Source: Karger Publishers - October 31, 2009 Category: Cancer & Oncology Source Type: journals